Emergent Biosolutions Inc. (EBS) Given Average Rating of “Buy” by Brokerages
Emergent Biosolutions Inc. (NYSE:EBS) has been given an average rating of “Buy” by the six ratings firms that are currently covering the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $37.50.
A number of research firms recently commented on EBS. Zacks Investment Research downgraded Emergent Biosolutions from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 5th. Wells Fargo & Co. set a $41.00 price objective on Emergent Biosolutions and gave the company a “buy” rating in a research report on Saturday, October 1st. Cowen and Company restated a “hold” rating and set a $33.00 price objective on shares of Emergent Biosolutions in a research report on Sunday, August 7th. JPMorgan Chase & Co. decreased their price objective on Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating on the stock in a research report on Friday, August 5th. Finally, Singular Research decreased their price objective on Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, June 28th.
A number of hedge funds and other institutional investors have recently made changes to their positions in EBS. Barclays PLC boosted its position in shares of Emergent Biosolutions by 13,232.1% in the first quarter. Barclays PLC now owns 20,798 shares of the biopharmaceutical company’s stock valued at $749,000 after buying an additional 20,642 shares during the period. Natixis purchased a new position in shares of Emergent Biosolutions during the first quarter valued at about $205,000. A.R.T. Advisors LLC boosted its position in shares of Emergent Biosolutions by 13.1% in the first quarter. A.R.T. Advisors LLC now owns 22,434 shares of the biopharmaceutical company’s stock valued at $815,000 after buying an additional 2,600 shares during the period. Springbok Capital Management LLC purchased a new position in shares of Emergent Biosolutions during the first quarter valued at about $192,000. Finally, Nuveen Asset Management LLC boosted its position in shares of Emergent Biosolutions by 4.8% in the first quarter. Nuveen Asset Management LLC now owns 60,685 shares of the biopharmaceutical company’s stock valued at $2,206,000 after buying an additional 2,785 shares during the period. 89.93% of the stock is currently owned by institutional investors.
Emergent Biosolutions (NYSE:EBS) traded down 1.74% during trading on Thursday, reaching $30.46. The company had a trading volume of 219,325 shares. The company has a market capitalization of $1.23 billion, a PE ratio of 21.79 and a beta of 1.12. Emergent Biosolutions has a one year low of $26.12 and a one year high of $44.38. The firm’s 50 day moving average is $28.61 and its 200 day moving average is $34.02.
Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.01. The firm earned $101.49 million during the quarter, compared to analysts’ expectations of $111.20 million. Emergent Biosolutions had a return on equity of 11.93% and a net margin of 11.61%. Emergent Biosolutions’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.36 earnings per share. On average, equities research analysts predict that Emergent Biosolutions will post $1.03 earnings per share for the current year.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.